CD137 Recombinant Protein Cat. No.: 90-409

Availability: In stock

$0.00

No Image

 Price Options

$0.00
psi-iconSpecifications
SPECIES:Human
SOURCE SPECIES:CHO cells
SEQUENCE:The extracellular domain of human CD137 [4-1BB] (aa 19-184) is fused to the N-terminus of the Fc region of human IgG1.
FUSION TAG:Fc Tag
TESTED APPLICATIONS:
APPLICATIONS:This recombinant proteins is for research use only.
BIOLOGICAL ACTIVITY: Measured by its binding ability in a functional ELISA.
psi-iconProperties
PURITY:>98% (SDS-PAGE).

Endotoxin level is less than 0.06EU/ μg protein (LAL test; Lonza).
PHYSICAL STATE:Lyophilized
BUFFER:Lyophilized from 0.2um-filtered solution in PBS. Reconstitute with 100 μl sterile water. Add 1X PBS to the desired protein concentration.
STORAGE CONDITIONS:Stable for at least 1 year after receipt when stored at -20˚C. Working aliquots are stable for up to 3 months when stored at -20˚C.
psi-iconAdditional Info
ALTERNATE NAMES:Tumor Necrosis Factor Receptor Superfamily Member 9, TNFRSF9, 4-1BB, 4-1BB Ligand Receptor T Cell, Antigen 4-1BB Homolog, T Cell Antigen ILA, CD137 Antigen, CDw137, ILA, MGC2172
ACCESSION NO.:AAH06196
PROTEIN GI NO.:13623201
OFFICIAL SYMBOL:TNFRSF9
GENE ID:3604
psi-iconBackground and References
BACKGROUND:Human CD137 (4-1BB) is a costimulatory molecule of the tumor necrosis factor (TNF) receptor superfamily. The glycoprotein 4-1BB is expressed mainly on activated CD4 + and CD8 + T cells and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. Upon ligand binding, 4-1BB is associated with the tumor receptor-associated factors (TRAF), the adaptor protein and mediates downstream signaling events including the activation of NF-kappaB and cytokine production. 4-1BB signaling either by binding to 4-1BBL or by antibody ligation delivers signals for T cell activation and growth as well as monocyte proliferation and B cell survival, and plays a important role in the amplification of T cell-mediated immune responses. In contrast, it can also enhance activation-induced T cell apoptosis when triggered by engagement of the TCR/CD3 complex. In addition, the 4-1BB/4-1BBL costimulatory pathway has been shown to augment secondary CTL responses to several viruses and increase antitumor immunity. 4-1BB is therefore a promising candidate for immunotherapy of human cancer.

FOR RESEARCH USE ONLY.

For additional information, visit ProSci's Terms & Conditions Page.